Imovane

Zopiclone, the active ingredient in Imovane, is a cyclopyrrolone presented as an oral tablet for oral use. It treats short‑term insomnia in adults by facilitating sleep onset and maintenance.

GNH USA supplies Imovane as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Zopiclone is a hypnotic agent used in the management of sleep disorders.

- Insomnia: improves overall sleep quality by reducing time to fall asleep and decreasing nocturnal awakenings. - Sleep onset difficulty: shortens the latency to the first sleep episode. - Sleep maintenance difficulty: reduces the frequency of early morning awakenings.

Zopiclone may cause a range of adverse reactions, most of which are dose‑related and transient.

Common Side Effects: - Drowsiness: feeling unusually sleepy during daytime. - Dry mouth: reduced salivary flow causing oral discomfort. - Headache: mild to moderate cranial pain. - Dizziness: sensation of light‑headedness or unsteadiness.

Serious or Rare Side Effects: - Complex sleep behaviours: activities such as sleep‑walking or driving while not fully awake. - Allergic reactions: rash, itching, swelling, or difficulty breathing. - Mood changes: depression, anxiety, or unusual thoughts. - Hallucinations: visual or auditory disturbances. - Respiratory depression: slowed breathing, particularly when combined with other depressants.

Before prescribing Zopiclone, clinicians should consider several safety measures.

- Assess renal function: adjust use in patients with impaired kidney function. - Avoid alcohol: concurrent consumption can intensify sedation. - Use caution in elderly: increased risk of falls and cognitive impairment. - Monitor for dependence: limit duration to the shortest effective period. - Do not operate machinery: avoid tasks requiring alertness until drug effects are known. - Store at ambient temperature: keep in the original pack, protect from moisture.

Zopiclone can interact with other substances that affect the central nervous system.

Major Interactions (Avoid): - Alcohol: additive sedative effect. - CNS depressants: enhanced sedation and respiratory depression. - Opioids: increased risk of profound CNS depression. - Barbiturates: potentiated sedative action.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin): may raise plasma levels. - Antidepressants (e.g., fluoxetine): can increase sedation. - Antihistamines: may augment drowsiness.